Established and emerging therapies for the treatment of viral hepatitis.
Patients who are chronically infected with either hepatitis B or C viruses run the risk of developing cirrhosis and hepatocellular carcinoma in later life. Antiviral treatment offers the only means of interrupting this progression. To date, recombinant interferon alpha and the nucleos(t)ide analogues lamivudine and adefovir dipivoxil are the only licensed drugs for the treatment of chronic hepatitis B, whilst recombinant or pegylated interferons in combination with ribavirin are the ones used for chronic hepatitis C virus infections. The efficacy of these treatments, reasons for treatment failure, drug resistance and future options are discussed in the present review.
Forton
Daniel
D
Department of Medicine A, Imperial College, St Mary's Campus, London, UK.
Karayiannis
Peter
P
D000998:Antiviral Agents / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome
D000998:Antiviral Agents